April 25, 2022
COVID-19 Health Care Fraud Enforcement on the Rise: What’s Ahead for the Life Sciences & Healthcare Industries
March 28, 2022
AdvaMed Updates Code of Ethics on Interactions with HCPs: What’s the Impact on MedTech?
August 17, 2021
Revised PhRMA Code Provides Stricter Controls on HCP Speaker Programs
February 3, 2021
Implementation of Final Rule Excluding PBM Rebates from Discount Safe Harbor Delayed Until 2023
January 15, 2021
General Counsel Internal Investigations Decision Tree for the Life Sciences Industry
November 25, 2020
HHS Finalizes Rule Challenging Drug Manufacturer Rebates to PBMs and Payors
November 24, 2020
Are Pharma Speaker Programs Facing an Existential Crisis?
October 17, 2019
HHS Issues Proposed Rule to Update Anti-Kickback Statute Safe Harbors – What Does it Mean for Life Sciences Companies?
April 21, 2017
New York Institutes New Medicaid Drug Price Control Measures
December 14, 2016
OIG Issues Final Rule Expanding Anti-Kickback Statute Safe Harbors and Revising Civil Monetary Penalty Regulations
August 25, 2015
OIG Issues Advisory Opinion Regarding Pharmaceutical Manufacturer Free Drug Program